Citi analyst Peter Verdult upgraded Hikma Pharmaceuticals to Buy from Neutral saying the company’s stronger growth deserves a premium multiple relative to European pharma peers and U.S. generics. https://thefly.com/landingPageNews.php?id=2880869
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.